+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 72 Pages
  • April 2023
  • GlobalData
  • Lonza Group AG
  • ID: 1291970
Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lonza Group Ltd (Lonza) is a contract manufacturing and development solutions company. It offers services including commercial mammalian and microbial manufacturing, clinical development, and manufacturing. It also offers high-potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities in Asia, Europe, and the Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd Key Recent Developments

  • Mar 29, 2023: Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
  • Mar 27, 2023: Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
  • Feb 16, 2023: Lonza completes expansion of conjugation facility in Visp (CH)
  • Jan 26, 2023: Lonza Group Announces Full Year Results 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Lonza Group Ltd - Key Facts
  • Lonza Group Ltd - Key Employees
  • Lonza Group Ltd - Key Employee Biographies
  • Lonza Group Ltd - Major Products and Services
  • Lonza Group Ltd - History
  • Lonza Group Ltd - Company Statement
  • Lonza Group Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Lonza Group Ltd - Business Description
  • Business Segment: Biologics
  • Overview
  • Performance
  • Business Segment: Capsules and Health Ingredients
  • Overview
  • Performance
  • Business Segment: Cell & Gene
  • Overview
  • Performance
  • Business Segment: Corporate
  • Performance
  • Business Segment: Small Molecules
  • Overview
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Australia & New Zealand
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North and Central America
  • Performance
  • Geographical Segment: Other countries
  • Performance
  • R&D Overview
  • Lonza Group Ltd - Corporate Strategy
  • Lonza Group Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Lonza Group Ltd - Strengths
  • Lonza Group Ltd - Weaknesses
  • Lonza Group Ltd - Opportunities
  • Lonza Group Ltd - Threats
  • Lonza Group Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Lonza Group Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 29, 2023: Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
  • Mar 27, 2023: Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
  • Feb 16, 2023: Lonza completes expansion of conjugation facility in Visp (CH)
  • Jan 26, 2023: Lonza Group Announces Full Year Results 2022
  • Oct 12, 2022: Gamma Biosciences and Lonza Collaborate to co-develop reagents for clinical cell selection in the cocoon platform
  • Sep 14, 2022: Lonza expands HPAPI Multipurpose Suite for Payload-Linker Manufacturing in Visp (CH)
  • Sep 12, 2022: Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
  • Sep 06, 2022: Lonza and Touchlight collaborate on end-to-end mRNA offering
  • Jul 22, 2022: Lonza delivers solid results in H1 2022 with sales growth of 16.8% (cc) and a CORE EBITDA margin of 33.1%
  • Jul 22, 2022: Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Lonza Group Ltd, Key Facts
  • Lonza Group Ltd, Key Employees
  • Lonza Group Ltd, Key Employee Biographies
  • Lonza Group Ltd, Major Products and Services
  • Lonza Group Ltd, History
  • Lonza Group Ltd, Other Locations
  • Lonza Group Ltd, Subsidiaries
  • Lonza Group Ltd, Joint Venture
  • Lonza Group Ltd, Key Competitors
  • Lonza Group Ltd, Ratios based on current share price
  • Lonza Group Ltd, Annual Ratios
  • Lonza Group Ltd, Interim Ratios
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Lonza Group Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Lonza Group Ltd, Performance Chart (2018 - 2022)
  • Lonza Group Ltd, Ratio Charts
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sannitree International
  • ADC Therapeutics SA
  • Royal DSM NV
  • Lisata Therapeutics Inc
  • Sannitree International
  • NBE-Therapeutics AG
  • Zep Inc
  • Dottikon ES Holding AG
  • Actelion Pharmaceuticals Ltd
  • Mabuhay Vinyl Corp
  • Dottikon ES Holding AG
  • NBE-Therapeutics AG
  • Zep Inc
  • Caladrius Biosciences Inc
  • Royal DSM NV
  • Actelion Pharmaceuticals Ltd
  • Mabuhay Vinyl Corp
  • ADC Therapeutics SA